[Improvement of ophthalmoplegia by 5-hydroxytryptophan in two cases of progressive supranuclear palsy].
We report two patients with clinically diagnosed progressive supranuclear palsy (PSP): a 69-year-old man and a 73-year-old woman. Both patients showed supranuclear ophthalmoplegia, postural instability, pseudobulbar palsy, and Parkinsonism. In the first patient, we administered L-dopa/carbidopa (300 mg/30 mg/ day), which moderately improved gait disturbance, but exerted no beneficial effects on gaze palsy. Then, we administered amitriptyline, bromocriptine, pergolide, l-threo-DOPS or 5-hydroxytryptophan (5-HTP) in addition to L-dopa/carbidopa. The second patient was treated by the monotherapy of L-dopa/carbidopa, amitriptyline, l-threo-DOPS or 5-HTP. We interposed two to three weeks between administration of each drug. In both patients, amitriptyline (75 mg/day) markedly improved both gait disturbance and horizontal gaze palsy. 5-HTP (600 mg/day) also improved horizontal gaze palsy, but failed to alleviate gait disturbance. The results suggest the involvement of impaired serotonergic system in ophthalmoplegia of PSP.
Yukitake
M
M
Department of Internal Medicine, Saga Medical School.
Takashima
Y
Y
Kurohara
K
K
Matsui
M
M
Kuroda
Y
Y
D006916:5-Hydroxytryptophan / Q000627:therapeutic use*; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D009886:Ophthalmoplegia / Q000188:drug therapy* / Q000209:etiology; D013494:Supranuclear Palsy, Progressive / Q000150:complications*
D006916:5-Hydroxytryptophan